Amgen plans launch of blockbusters' biosimilars in 4 years

02/8/2013 | Reuters

Amgen intends to commercialize biosimilar versions of six of the biggest-selling biologic drugs including Humira and Remicade, the main rivals of its own rheumatoid arthritis treatment Enbrel, starting in 2017, CEO Robert Bradway said. The biotech firm sees biosimilars as a multi-billion dollar opportunity, and it expects to become a major player in the market once the approval pathway is finalized.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ